Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...

BioNTech stock has climbed 25% over four days as the German biotech rides a round of cancer treatment success from Summit ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...

Shares of Summit Therapeutics Inc. jumped more than 30% premarket on Monday after the biotech company released late-stage ...

Summit Therapeutics (NASDAQ: SMMT) recently reported Ivonescimab’s Phase 3 results from study conducted in China that showed ...

Summit Therapeutics' ivonescimab shows a significant PFS improvement over pembrolizumab in NSCLC. Read why I'm bearish on ...

Summit Therapeutics presents updated Ivonescimab data from phase II studies at ESMO 2024 annual meeting: Miami Wednesday, September 18, 2024, 15:00 Hrs [IST] Summit Therapeutics I ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as ...

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...